RT Journal Article SR Electronic T1 O019 Extra-genital samples for gonorrhoea and chlamydia in women and MSM: Self-taken samples analysed separately compared with self-taken pooled samples JF Sexually Transmitted Infections JO Sex Transm Infect FD BMJ Publishing Group Ltd SP A7 OP A7 DO 10.1136/sextrans-2016-052718.18 VO 92 IS Suppl 1 A1 Wilson, Janet A1 Wallace, Harriet A1 Loftus-Keeling, Michelle A1 Ward, Helen A1 Hulme, Claire A1 Wilcox, Mark YR 2016 UL http://sti.bmj.com/content/92/Suppl_1/A7.2.abstract AB Background Extra-genital infections are common in MSM and women and are frequently the sole sites of infection. However, analysing samples from the rectum and pharynx, in addition to the urogenital tract, trebles the diagnostic cost.Aim Can samples from three sites be pooled into one NAAT container and still achieve the same sensitivity and specificity as the samples analysed separately?Methods Women and MSM attending a sexual health clinic were invited into a ‘swab yourself’ trial. Two self-taken samples (one for separate analysis and one for pooling) were taken from the pharynx and rectum with VVS in women and FCU in MSM. The sampling order of the pooled or analysed separately swabs was randomised. Gonorrhoea (NG) and chlamydia (CT) were diagnosed using NAATs. Patient infected status was defined as at least two positive confirmed samples.Results 1251 women and MSM were recruited to January 2016. Overall prevalence of infections was NG 5.7% and CT 17.8%. Sensitivity, specificity, PPV and NPV are shown in the table:View this table:Abstract O019 Table 1 Sensitivity & specificity of separate and pooled samplesConclusion This on-going study demonstrates that self-taken samples from the rectum, pharynx and urogenital tract are comparable in sensitivity and specificity if analysed separately or as a pooled sample. In MSM the diagnostic costs of three separate analyses are unaffordable for many health systems but a pooled sample has the same laboratory cost as a urogenital sample. These findings mean triple site testing could be expanded into women at no additional health service cost.